NeoGenomics Reports 17% Revenue Growth to Record $69 Million
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/9/2026
- Nasdaq ends sharply higher; chip surge offsets Iran worries
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Applied Materials surges as CEO signals multi-year chip boom
- Oil prices settle 2% lower as economic worries outweigh supply risks
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- GameStop stockholders approve share count increase to 2.5 billion
- Crude Inventory Rose 3 Million Barrels Last Week - EIA
- AI bubble fears mount as Zuckerberg admits agent delays and Burry shorts sector
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
NeoGenomics (NEO) Tops Q3 EPS by 3c, Beats on Revenues; Lifts FY18 EPS/Revenue Outlook Above Consensus
October 30, 2018 7:12 AM EDTNeoGenomics (NASDAQ: NEO) reported Q3 EPS of $0.05, $0.03 better than the analyst estimate of $0.02. Revenue for the quarter came in at $69.1 million versus the consensus estimate of $66.33 million.
Douglas M. VanOort, the Companys Chairman and CEO, commented, Third quarter results were outstanding. Clinical and Pharma Services Divisions each reported record revenue. Test volume... More
